People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides
Arrowhead Pharmaceuticals (NASDAQ: ARWR) said the European Commission approved REDEMPLO (plozasiran) in June 2026, and it is now listed in Germany’s Lauer-Taxe database for prescribing and reimbursement. REDEMPLO is used with diet for adult FCS patients, with dosing as a subcutaneous injection every three months. Phase 3 PALISADE showed significant fasting triglyceride reductions at Month 10 versus placebo; common adverse reactions included hyperglycaemia and headache.
How this was made
The 30-second read
Why it matters
The key incremental development is Germany’s ability to prescribe and reimburse REDEMPLO following EU marketing authorization, which can shorten time-to-treatment for eligible patients diagnosed clinically or genetically.
Market read
This is a commercialization milestone for Arrowhead’s lead asset in a major EU market, likely to be treated as incremental progress toward revenue generation.
What to watch
The release provides efficacy and adverse reactions but no pricing, reimbursement level, or sales guidance, so the market may still discount the financial magnitude until launch metrics emerge.
Background
REDEMPLO (plozasiran) is positioned as an adjunct to diet for adult familial chylomicronaemia syndrome (FCS), with dosing as a subcutaneous injection every three months.
Ticker impact
Arrowhead says the European Commission approved REDEMPLO (plozasiran) and it is now listed in Germany’s Lauer-Taxe for prescribing and reimbursement.
Likely positive bias for ARWR as the market prices incremental commercialization progress in Europe, though magnitude depends on reimbursement and launch execution.
The article is a first-time, concrete regulatory/commercial milestone (EU approval in June 2026, Germany listing now) plus dosing and Phase 3 efficacy/safety recap, which can drive incremental demand expectations.
Market effects
Reinforces momentum for RNAi therapeutics in rare metabolic disease and may improve investor appetite for similar gene-silencing platforms.
Germany becomes the first EU focus for REDEMPLO availability, potentially accelerating European revenue ramp expectations for Arrowhead.
EU commercialization progress can influence how investors value Arrowhead’s pipeline and future country-by-country approvals.
Counterpoint
A Germany listing does not guarantee rapid patient uptake; reimbursement terms, physician awareness, and diagnostic pathways could limit near-term sales impact.
Key entities
- companyArrowhead Pharmaceuticals, Inc.
Commercial-stage RNAi therapeutics company announcing Germany access for REDEMPLO after EU marketing authorization.
- drugREDEMPLO (plozasiran)
RNAi therapy for FCS, authorized for use alongside diet and dosed subcutaneously every three months.
- diseaseFamilial Chylomicronaemia Syndrome (FCS)
Rare metabolic condition with extremely high triglycerides and elevated acute pancreatitis risk.
- clinical trialPALISADE study
Phase 3 placebo-controlled study supporting regulatory approval, with primary endpoint at Month 10 fasting triglyceride change.
